10-K: Greater Cannabis Company Reports $0 Revenue for 2023, Net Loss of $188,402

The Greater Cannabis Company reported no revenue and a net loss of $188,402 for the year ended December 31, 2023, while highlighting ongoing concerns about its ability to continue as a going concern.

Summary

• The Greater Cannabis Company reported $0 in revenue for the year ended December 31, 2023, the same as in 2022.
• The company's operating expenses were $175,364 in 2023, slightly down from $177,035 in 2022.
• The net loss for 2023 was $188,402, an improvement from the $360,268 loss in 2022.
• The company had $166,859 in cash on hand at the end of 2023, compared to $270,030 at the end of 2022.
• Convertible notes payable decreased to $171,437 in 2023 from $243,437 in 2022.
• The company's financial statements indicate a working capital deficit of $666,649 and an accumulated deficit of $4,481,304 as of December 31, 2023.
• The report expresses substantial doubt about the company's ability to continue as a going concern, dependent on improving profitability and securing additional financial support.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to the lack of revenue, significant losses, decreasing cash reserves, and a going concern warning. The company's financial situation is precarious, and its future is highly uncertain.

Positives

• The company's net loss decreased significantly from $360,268 in 2022 to $188,402 in 2023.
• Operating expenses saw a slight decrease year-over-year.
• The principal amount of outstanding convertible notes decreased from $243,437 to $171,437.

Negatives

• The company generated no revenue in both 2022 and 2023.
• The company experienced a decrease in cash reserves from $270,030 to $166,859.
• The company has a substantial working capital deficit of $666,649.
• The company has an accumulated deficit of $4,481,304.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is highly dependent on securing additional funding and improving profitability.
• The company faces risks related to government regulation of the marijuana industry.
• The company is subject to risks related to the inherent uncertainty of business operations including profit, cost of goods, production costs and cost estimates and the potential for unexpected costs and expenses.
• The company faces risks related to failure to obtain adequate financing on a timely basis and on acceptable terms for planned development projects.
• The company has identified material weaknesses in its internal control over financial reporting and disclosure controls and procedures.
• The company may not be able to meet the requirements of agreements under which it acquired business interests.
• The company may be unable to secure additional financing in the near future to sustain its growth plans.
• The company may not be able to attract, retain, and motivate qualified personnel.

Future Outlook

The company's future operating results, liquidity, and capital resources will be significantly affected by government regulation of the marijuana industry, revisions of federal banking regulations, and the legalization of marijuana in more states. The company expects to continue to incur negative cash flows until its business generates sufficient cash inflows to finance operations and debt service requirements.

Management Comments

• Management believes the existing shareholders or external financing will provide additional cash to meet the company's obligations as they become due.
• Management has determined that, as of December 31, 2021, the company's internal control over financial reporting was not effective.
• Management is responsible for establishing and maintaining adequate internal control over financial reporting.

Industry Context

The company operates in the competitive cannabis space, facing competition from various companies including producers, edible product makers, and developers of cannabis delivery methods. The company specifically names Jazz Pharmaceuticals and Zynerba Pharmaceuticals as competitors in their space. The industry is subject to evolving regulations and market dynamics.

Comparison to Industry Standards

• The company's lack of revenue is a significant deviation from industry norms, as most cannabis companies generate some level of sales.
• The company's reliance on external financing and its going concern warning are not uncommon for early-stage cannabis companies, but the severity of the situation is concerning.
• The company's focus on cannabinoid therapeutics is a growing area within the industry, but the lack of progress in commercialization is a major challenge.
• Compared to companies like Jazz Pharmaceuticals and Zynerba Pharmaceuticals, which have established revenue streams and clinical programs, The Greater Cannabis Company is significantly behind in development and commercialization.

Related Party Transactions

• The company leases office space from its chief executive officer, Aitan Zacharin, for no consideration.
• Loans payable to related parties include $180,000 from Elisha Kalfa and Yonah Kalfa and $80,000 from Fernando Bisker and Sigalush, LLC.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees are at risk due to the company's uncertain future and potential for operational curtailment.
• Creditors face increased risk of non-payment due to the company's financial difficulties.
• Customers and suppliers are impacted by the company's uncertain future and potential for operational curtailment.

Next Steps

• The company intends to allocate additional funds of approximately $250,000 from financing proceeds to research and development, sample productions and preclinical studies.
• The company will continue to monitor the effectiveness of its actions to mitigate material weaknesses in internal controls.
• The company intends to evaluate its processes and procedures and, where practicable and resources permit, implement changes in order to have more effective controls over financial reporting.

Key Dates

Keywords

cannabis, cannabinoid therapeutics, financial results, going concern, net loss, convertible notes, operating expenses, revenue, internal control, biopharmaceutical